脑电生物反馈联合舍曲林治疗青少年抑郁症非自杀性自伤行为的效果观察

Objective To explore the efficacy and safety of sertraline combined with electroencephalogram(EEG) biofeedback therapy for non-suicidal self-injury(NSSI) in adolescents with depression. Methods A total of 122 adolescent patients with depression and non-suicidal self-injury(NSSI) behavior admitted between August 2023 and October 2025 were enrolled as the primary study participants. Stratified randomization was performed to divide them into two groups based on age and disease severity, with 61 cases in each group. The control group received sertraline monotherapy, while the observation group was treated with sertraline combined with electroencephalographic(EEG) biofeedback. The treatment duration was 8 weeks. The two groups were compared in terms of improvements in depressive symptoms and NSSI behavior, as well as adverse reactions, both pre-and post-treatment. Results The improvement of depression symptoms and NSSI behavior inhibition effect in the observation group were better than those in the control group. Compared with the control group the Children's Depression Inventory(CDI) score, the number of frequency, mode and parts of self-injury in the observation group were significantly reduced after 4 and 8 weeks of treatment(P<0.05). The safety of the two groups was controllable, and there was no difference in adverse reactions between the two groups(P>0.05). Conclusions EEG biofeedback combined with sertraline can significantly improve the disease manifestations of adolescent patients with depression and NSSI behavior, reduce the occurrence self-harm behaviors, and the adverse reactions are easy to tolerate.